

List of changes to the ANZTCT Cell Therapy Guidelines

Version 3.1 June 2026

CORE FORMS			
Form name	Section	Change	Description
CT Pre-infusion	2. Cell therapy		Added option 'NA, compassionate use' to Product Funding
		New	Indication for Carvykti, select appropriate following prior treatment criteria 5L, 4L or 2L.
	8. Bridging Therapy	New	Added type of bridging therapy: chemotherapy, immunotherapy and radiotherapy. Added stop date of bridging therapy.
	13. Comorbid conditions	New	Added Prior solid organ transplant questions.
CT Infusion	1. Cell Product Identifiers	New	Add table of source documentation for the product identifiers
	3. Cell Doses	Modified	Total number of cells are not required. Report cell doses for Kymriah and Carvykti only as Lymphocyte unselected. Extra instruction is added for Commercial Carvykti and Kymriah.
CT Follow Up	2. Survival	Modified	Report survival date at 30day follow-up +/- 7 days.
	9. Persistence Of Cells	New	Was another infusion given for loss of B-cell aplasia
	11. Toxicities - CRS	New	Start date of first therapy for CRS. New questions specific to IEC-HS – including associated fever, organ toxicities, and date resolved.
	11. Toxicities - CRS	Modified	Relabelled MAS/HLH with IEC-HS, immune effector cell (IEC) associated HLH-like syndrome (IEC-HS)

DISEASE FORMS			
Form name	Section	Change	Description
	All sections	New	Additional instructions (diagrams) to aid navigation in the CIBMTR instruction manual website for each diagnosis at pre and post infusion, and disease response criteria.
Disease Classification Form			Clarification between sections A and B
Disease Classification Form	Multiple myeloma	New	Myeloma characteristics, assessments at diagnosis and prior to infusion
The Latest disease status is same as reported in Section 3, without subsequent treatment	ALL Post Infusion – 5. Disease Evaluation for this reporting period	Modified	Change formatting to clarify intention of the question
Lymphoma Post Infusion	4. Therapy for relapse or progression	Modified	Clarify to report therapy given for MRD, only if this is a newly developed MRD. Do not include here if it was existing at the time of cell therapy infusion.
Myeloma Pre-infusion		New form	Disease assessments, treatment prior to infusion
Myeloma Post Infusion		New form	Disease response and relapse/progression and associated assessments. Disease treatment post infusion
	Appendix	New	Disease response criteria for Myeloma

Heading	Section	Change	Description
General			Introduced separate guidelines for: <ul style="list-style-type: none"> • Core cell therapy forms • Disease forms
General			'ANZTCT' replaces 'ABMTRR' throughout the documents, including links to webpages to registry
General			Some lists of data options and images (screenshots of questions in Redcap) have been removed as they may not provide extra guidance in this document

Purpose Of These Guidelines		New	Description
Registration Requirements		Modified	Added EQ-5D to forms required as was omitted at registration Added flow diagram describing criteria in creating new patient form
Form Submission Workflow		Modified	Simplified diagram
General Guidelines For Completing Forms	Guide for entering data	Modified	Expanded to include reporting lab values <, > and range of numbers
General Guidelines For Completing Forms	Data Requirements for Cell Products Not infused		Updated with new requirements
CT Pre-infusion	Patient Assessment		Added ECOG table
CT Pre-infusion	Co morbidities		Table updated Timeframe of assessments to include
CT Pre-infusion	2. Cell Therapy	New	Axicabtagene funding
	13. Comorbid Conditions	New	Prior viral exposure/infection(s)
	13. Comorbid Conditions	Removed	COVID-19 questions
	13. Comorbid Conditions	Modified	Updated the definition/criteria in the Comorbidity table
Cell Therapy Infusion	1. Cell Product Identifiers	Modified	Batch number - added Carvykti
	1. Cell Product Identifiers	Add	Lot number (Yescarta and Tecartus) Lot number Format = 9 digits with a possible 2-digit extension
CT Follow Up	12. Toxicities – Neurotoxicity	Removed	CARTOX score
Quality Of Life		Added	Please note that the ANZTCT REDCap database cannot email these directly to the patient. The ‘Send email invitation?’ question is displayed at the top of the forms as a requirement by EuroQol, however it cannot be utilised.
Disease Classification Form			Re-worded Disease Classification Form Part A and Disease Specific Forms Part B headings for clarification
Disease Forms			New images to describe components of the disease forms Parts A and B

			New images to help find the appropriate forms and questions on the CIBMTR website.
			Date of diagnosis clarified for transformed lymphoma
Disease Forms		New appendix	Disease response criteria for ALL and Lymphoma